Ginkgo Bioworks Holdings, Inc. (DNA) News
Filter DNA News Items
DNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DNA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest DNA News From Around the Web
Below are the latest news stories about GINKGO BIOWORKS HOLDINGS INC that investors may wish to consider to help them evaluate DNA as an investment opportunity.
Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare ConferenceGinkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 a.m. PT (1:30 p.m. ET). |
All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to BuyGinkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT ProgramGinkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to $9.4 million awarded in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices aimed at diagnosing and treating hormone disorders. This initiative is part of the Advanced Research Projects Agency for Health's (ARPA-H) Resilient Extended Automatic Cell Therapies (REACT) program. Ginkgo is eligible to receive up to $9.4 mi |
Ginkgo Bioworks Holdings Third Quarter 2024 Earnings: Beats ExpectationsGinkgo Bioworks Holdings ( NYSE:DNA ) Third Quarter 2024 Results Key Financial Results Revenue: US$89.0m (up 61% from... |
Ginkgo Bioworks Reports Third Quarter 2024 Financial ResultsGinkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information will be available at investors.ginkgobioworks.com. |
Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics ManufacturingGinkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of a previously announced partnership with Merck, known as MSD outside of the United States and Canada, focused on improving biologic manufacturing. As part of this milestone completion, Ginkgo will receive a research milestone payment of $9 million in cash. |
Ginkgo Bioworks Announces Date of Third Quarter 2024 Results PresentationGinkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, beginning at 5:30 p.m. ET. |
With 48% ownership, Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has piqued the interest of institutional investorsKey Insights Given the large stake in the stock by institutions, Ginkgo Bioworks Holdings' stock price might be... |
NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal AgricultureToday, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced its new partnership with NOVUS International, an innovator and leader in intelligent nutrition, to develop advanced feed additives designed to meet the evolving needs of the animal agriculture industry. By utilizing Ginkgo Enzyme Services, NOVUS will work with Ginkgo to build more efficient enzymes that can be produced cost-effectively. |
Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in BiologyToday, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient. Ginkgo Datapoints is specialized in generating large, high-quality biological datasets with a fast turnaround time and at a competitive price per datapoint with a streamlined deal structure. Ginkgo Datapoints will launch with severa |